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Long-term beneficial effect of ACE inhibition on diabetic
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Long-term beneficial effect of ACE inhibition on diabetic ne- The clinical syndrome of diabetic nephropathy is char-
phropathy in normotensive type 1 diabetic patients. acterized by a progressive rise in albuminuria and arterial
Background. The purpose of this study was to assess whether blood pressure (BP) associated with a relentless declinelong-term (8 years) inhibition of angiotensin-converting en-
in glomerular filtration rate (GFR) of approximately 10zyme (ACE) protects kidney function in normotensive type 1
to 14 mL/min/year [1]. Even though arterial hypertensiondiabetic patients with diabetic nephropathy.
Methods. We performed an open randomized follow-up is an early and frequent phenomenon [2, 3], normoten-
study of normotensive type 1 diabetics with nephropathy either sion is present in approximately 25% of the cases when
treated (N  15) or not (N  17) with captopril twice per day kidney function is well preserved [2, 3]. Previous studies(average 74, range 12.5 to 125 mg/day). The main outcome
have clearly documented that BP elevation and albumin-measures were arterial blood pressure, albuminuria, and glo-
uria are powerful progression promoters, as reviewed bymerular filtration rate (GFR; 51Cr-EDTA plasma clearance,
twice yearly). Rossing [4]. In complete agreement herewith, antihyper-
Results. Arterial blood pressure (mm Hg) was kept constant tensive treatment has been shown to reduce albuminuria
in the captopril group, at baseline (mean, SEM), 128/78 (3/2) and postpone end-stage renal disease (ESRD) in hyper-
and during follow-up 129/77 (4/1) but increased significantly
tensive type 1 diabetic patients with persistent albumin-in the control group from 127/79 (2/1) to 137/84 (5/2) (P 
uria [5]. Information is lacking on treatment modalities,0.01). Furthermore, 8 out of the 17 control subjects required
treatment with blood pressure-lowering drugs because they including BP-lowering agents with a beneficial effect on
developed hypertension. The fractional albumin clearance kidney function in normotensive type 1 diabetic patients
(105) remained unchanged in the captopril group: baseline with diabetic nephropathy. In contrast, studies in normo-
[10.8 (1.25) geometric mean and antilog (SEM)] during the
tensive streptozotocin diabetic rats have demonstratedeight years [11.8 (1.47)], while a significant rise occurred in
that angiotensin-converting enzyme (ACE) inhibitioncontrol patients: 13.3 (1.23) to 26.2 (1.42) (P  0.05). Baseline
initiated at diabetes onset confers long-term protectionGFR was nearly identical: 111 (6) and 115 (4) mL/min/1.73 m2
in the captopril and control group, respectively. The median against the development of diabetic glomerulopathy
(range) rate of decline in GFR (mL/min/year) was 1.7 (10.7 to (primary prevention) [6]. Long-term ACE inhibition and
2.0) in the captopril group versus 2.8 (17.7 to 2.6) in the treatment with calcium channel blockers can delay thecontrol group (P  NS).
development of diabetic nephropathy in normotensiveConclusions. The beneficial effect of captopril in arresting
type 1 diabetic patients with persistent microalbuminuriathe rise in systemic blood pressure and albuminuria is long
lasting. A loss in GFR is minimal in most patients with diabetic (secondary prevention) [7]. Recently, our group has
nephropathy if normotension is sustained by prospective treat- shown that the beneficial effect of ACE inhibition in the
ment with ACE inhibitors or restored by implementation of prevention of diabetic nephropathy in type 1 diabeticother antihypertensive medications with the development of
patients is long lasting and is associated with the preser-hypertension.
vation of normal GFR [8].
We assessed whether long-term (8 years) inhibition of
ACE protects kidney function in normotensive type 1
diabetic patients with diabetic nephropathy. The impact
of a two-month treatment pause on albuminuria and
Key words: albuminuria, kidney function, arterial blood pressure, end- GFR was also investigated. An interim report after one
stage renal disease, glomerular filtration rate, hypertension, renopro- year of study has previously been published [9].
tection.
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Table 1. Clinical and laboratory data at baseline in normotensive treatment with BP-lowering drugs during the investiga-
type 1 diabetic patients with diabetic nephropathy
tion period (diuretics, dihydropyridine calcium antago-
Captopril- nist, and  blocker). Treatment was initiated because of
Parameter treated group Control arterial BP elevation (160/95 mm Hg) with (N  3) or
Number and sex 5 F, 10 M 4 F, 13 M without (N 5) edema formation. All patients had been
Age years 32 (8) 30 (8)
insulin dependent from the time of diagnosis, and allDuration of diabetes years 20 (8) 20 (8)
N with simplex/proliferative were at least receiving two daily injections of highly puri-
retinopathy 10/5 9/8 fied porcine insulin. All patients were on their usual dia-
Vibratory perception threshold
betic diet without sodium or protein restriction. Diabeticvolts 15 (8) 21 (16)
Hemoglobin A1c % 9.5 (1.6) 8.7 (0.8) nephropathy was diagnosed clinically on the basis of per-
Insulin dose U/kg/24 h 0.66 (0.20) 0.64 (0.20) sistent albuminuria (300 mg per 24 h), presence of dia-
Protein intake g/24 h 77 (27) 80 (23)
betic retinopathies, and the absence of any clinical or labo-Urinary sodium excretion
mmol/min 0.16 (0.02) 0.15 (0.02) ratory evidence of other kidney or renal tract disease [10].
Body mass index kg/m2 22.2 (2.3) 22.9 (1.6) The investigation in each patient was carried out be-
Values are means (SD). tween 8:00 a.m. and 1:30 p.m. The patients had their
usual breakfast and morning insulin. The patients were
supine during the entire investigation except when uri-
nating. The patients drank 200 mL tap water per hour
who visited the outpatient clinic at Hvido¨re Hospital in
during the procedures. The clearance studies were car-
1985. One hundred seven patients with arterial hyperten-
ried out every six months. GFR was measured after a
sion (160/95 mm Hg; World Health Organization crite- single intravenous injection of 3.7 MBq chromium-51–
ria) were excluded from further investigation. The re- labeled edetic by studying its disappearance in plasma
maining patients (N  73) were invited to participate if over four hours [11]. The mean intra-individual coeffi-
they fulfilled the following criteria: persistent albumin- cient of variation of GFR from day to day was 4.0% in
uria (300 mg/24 h), serum creatinine concentration our laboratory. Albuminuria was measured during the
120 mol/L, or a GFR 60 mL/min/1.73 m2, average four-hour clearance period by radioimmunoassay in all
of three or more consecutive BP readings below 150/90 urine samples to 1992. The assay has a sensitivity of 0.5
mm Hg, no edema, not taking other drugs apart from mg/L and a coefficient of variation of 9% [12]. After
oral contraceptives, age of less than 50 years, and onset 1992, an enzyme-linked immunosorbent assay (ELISA)
of diabetes before the age of 41. Thirty-five patients method was used with a sensitivity of 0.01 mg/L and a
(19%) fulfilled these criteria, of whom two men refused coefficient of variation of 8.3% [13]. The correlation
the trial; the remaining 33 patients gave fully informed between the two methods was r 0.99. Fractional clear-
consent. The study was approved by the scientific ethics ance of albumin was obtained by dividing the clearance
committee of Copenhagen County (Table 1). of albumin (calculated as UV/P, where U is urine albu-
The patients were matched in pairs according to albu- min concentration, V is urine flow, and P is plasma albu-
minuria, arterial BP, and GFR levels, and were random- min concentration) by the simultaneous measured GFR.
ized (concealed) either to receive captopril (N  16) or BP was measured with Hawksley random zero device
not to receive hypotensive treatment (controls; N 17). (cuff size 25  12 cm) on the right arm. Two readings
One woman with persistent microscopic hematuria, both were taken at the beginning, middle, and end of each
before and during the first eight months of treatment clearance period. Two readings were also taken when
with captopril, was excluded from the study and from the patients visited the outpatient clinic between 2:00
the statistical analysis because the kidney biopsy showed and 4:00 p.m. Diastolic BP was recorded at the point of
mesangioproliferative glomerulonephritis superimposed disappearance of the Korotkoff sounds (phase V). Mean
on diffuse diabetic glomerulosclerosis. This left 15 patients BP was calculated as the diastolic BP plus one third of
in the captopril group. Treatment with captopril was the pulse amplitude.
aimed primarily at preventing the rise in arterial BP Blood glucose concentration was measured hourly
that occurs in diabetic nephropathy and secondarily at during the four-hour clearance period by reflectance me-
reducing the mean arterial BP by 5 mm Hg. Initially, ter (Reflomat; Boehringer Mannheim, Ingelheim, Ger-
all treated patients received 12.5 mg captopril before many). Leukocyte counts and measurement of serum
breakfast and dinner. The dose was adjusted at the visits electrolyte, albumin, hemoglobin, and cholesterol con-
to the outpatient clinic (once per month until the third centrations during each investigation were carried out by
month, and once every 3 months thereafter). The capto- conventional laboratory techniques. Stable hemoglobin
pril-treated group received captopril b.i.d., with an aver- A1c was measured before and at each investigation (nor-
age of 74 mg/day (12.5 to 125 mg/day) at the eight-year mal range of 4.1 to 6.1% of total hemoglobin). Twenty-
four–hour urine collections were used for calculatingfollow-up. Eight out of the 17 control patients started
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Table 2. Effects of captopril on arterial blood pressure, albuminuria, rate of decline in glomerular filtration rate (GFR)
in normotensive type 1 diabetic patients with diabetic nephropathy during 8 years of follow-up
Captopril (N  15) Control (N  17)
During 8 years During 8 years
Baseline follow-up Baseline follow-up
Arterial blood pressure mm Hg 128/78 (3/2) 129/77 (4/1) 127/79 (2/1) 137/84 (5/2)b
Albuminuriaa mg/24 h 838 (x/1.15) 657 (x/1.29) 1140 (x/1.16) 1379b (x/1.17)
GFR mL/min/1.73 m2 111 (6) 98 (8)c 115 (4) 97 (6)c
GFRd mL/min/year 1.7 (10.7 to 2.0) 2.8 (17.7 to 2.6)
Values are means (SE).
a Geometric mean (x/antilog SE)
b P  0.02, comparison between captopril and control means during the entire 8-year follow-up period
c Values at end of follow-up
d Median (range)
protein intake from the urinary urea nitrogen and an and age) and rate of decline in GFR. All calculations
were made with a commercially available program Stat-estimated nonurea nitrogen excretion of 31 mg/kg/day.
Given a constant nitrogen balance, nitrogen intake equals graphic (STSC, Rockville, MD, USA).
urinary urea nitrogen excretion and nonurea nitrogen
excretion, protein intake (g/day)  nitrogen  6.25.
RESULTSAfter eight years, 10 out of the 15 captopril-treated
The two groups were well matched at baseline (Tablespatients and 4 out of 8 control patients receiving non-
1 and 2). The average captopril dose was 74 (12.5 to 125)ACE inhibition antihypertensive drugs from the control
mg/daily given two times per day during follow-up. Fivegroup were subsequently investigated after a BP-lowering
out of 17 patients in the control group developed arterialtreatment pause of two months (Table 3). The reasons
hypertension (repeated recording 160/95 mm Hg) andfor not conducting this investigation in the remaining
were treated with diuretics (N  3), dihydropyridine cal-five patients in the captopril-treated group were dead in
cium antagonist (N  3), and -blockers (N 1). In addi-bed (N  1), hemodialysis (N  1), emigration (N  1),
tion, three patients in the control group developed edemacombined diabetic glomerulosclerosis and glomerulone-
and BP elevation requiring treatment with diuretics. Inphritis (N  1), and intercurrent illness (N  1). The
total, 8 out of 17 control patients received BP-loweringreasons in the four control patients included ESRD (N3)
drugs.and stroke (N  1). BP, albuminuria, and GFR were
The median initial decline in GFR (mL/min) duringmeasured using the previously mentioned methods.
the first six months of the study was 8 (12.9 to 1.1) and
Statistical analysis 2 (9.9 to 0.6) in the captopril-treated group compared
with the control group (P  NS).An intention-to-treat strategy in the statistical analysis
The average values and the course of arterial BP,was applied since all patients (captopril, N  15, and
GFR, and fractional albumin clearance are shown incontrol, N  17) who completed the first 12 months
Table 2 and Figure 1. A comparison between the meanof the study period were included. Variables measured
value of arterial BP and geometric valve of albuminuriaduring the trial for each patient (N 32) are summarized
revealed significantly lower values of both variables inby one mean variable of all measurements over the entire
the captopril-treated group as compared with the controltreatment period for that patient. Descriptive informa-
group (P  0.05). Figure 1 shows that the separationtion is expressed as means and SD, and results are ex-
between these two variables occurs right from the startpressed as mean and SE. Albuminuria and fractional
of captopril treatment. The rate of decline in GFR wasalbumin clearance are given as geometric mean x/ anti-
1.7 (10.7 to 2.0) mL/min/year and 2.8 (17.7 to 2.6)log SE due to their positively skewed distribution. The
paired and unpaired Student t tests were used, and a P mL/min/year in the captopril-treated versus the control
group, respectively (P  NS).value of 0.05 (two tailed) considered significant. The
rate of deterioration of renal function was analyzed by In univariate analyses, no significant correlation was
found between the rate of decline in GFR during theregression lines for 51Cr-EDTA clearance over time, de-
termined for each patient over the entire study period. study and the following baseline variables: albuminuria,
hemoglobin A1c, systolic and diastolic BP, urinary sodiumLinear regression and stepwise linear regression analysis
were used to evaluate the correlation between putative excretion, dietary protein intake, and the age of the pa-
tient. During follow-up period, a significant univariatepredictors (albuminuria, BP, hemoglobin A1c, baseline
GFR, urinary sodium excretion, dietary protein intake, correlation between the rate of decline in GFR and albu-
Parving et al: ACE inhibition in diabetic nephropathy 231
Fig. 1. (A–C) Average course of systemic blood
pressure (BP), glomerular filtration rate (GFR),
and fractional albumin clearance is shown in
type 1 diabetic patients with nephropathy
treated with angiotensin-converting enzyme
(ACE) inhibition () or not (control group;
). Eight out of 17 control patients required
treatment with BP-lowering drugs because ar-
terial BP elevation 160/95 mm Hg. Systemic
BP and fractional albumin clearance were
both significantly lower than the control group
(P  0.05).
minuria and systolic and diastolic BP were demonstrated between fast and slow progressors. One patient died in
each group, but three control patients developed ESRD,(P  0.05), while the remaining variables mentioned
previously in this article showed no significant correla- requiring dialysis or transplantation.
Four men (one treated with captopril) had a suddention. In a multivariate model, high values of albuminuria
and systolic BP during the observation period were asso- onset of nephrotic-range albuminuria. Consequently, a
kidney biopsy was performed revealing only diffuse dia-ciated with enhanced decline in GFR, independently of
the randomized group (adjusted R2  0.60). betic glomerulopathy in three patients, while the last
patient (control) had combined diabetic glomerulopathyThe huge variability in the individual rate of decline
in GFR is depicted in Figure 2. The five patients with a and glomerulonephritis. Asymptomatic microscopic he-
maturia was present in that patient. This patient wasrate of decline in GFR 10 mL/min/year had signifi-
cantly higher albuminuria and total cholesterol (P  excluded from further follow-up at three years, but was
included in the intervention-to-treat analysis.0.05), while other putative progression promoters such
as BP, hemoglobin A1c, and protein intake did not differ Even though it was only possible to evaluate the two-
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by ACE inhibition was completely regained after two
months off of the ACE inhibition treatment. One-half
of the control patients developed arterial hypertension
requiring treatment with BP-lowering drugs (non-ACE
inhibitors). Finally, short-term withdrawal (two months)
of long-term BP-lowering treatment (eight years) induced
a significant rise in arterial BP, albuminuria, and GFR.
The natural course of diabetic nephropathy is charac-
terized by a progressive rise in albuminuria and arterial
BP associated with a relentless decline in GFR of approx-
imately 10 to 14 mL/min/year [1]. This information was
generated from studies not applying antihypertensive
treatment. The rise in albuminuria and BP was much less
in our study than observed in the previously mentioned
studies, but half of our control (“untreated”) patients
Fig. 2. Individual course of glomerular filtration rate (GFR) is depicted received antihypertensive treatment because they devel-
in type 1 diabetic patients with nephropathy treated with angiotensin- oped hypertension. It is well documented that BP-low-converting enzyme (ACE) inhibition () or belonging to the control
ering drugs reduce BP, diminish albuminuria, and slowgroup (). Eight out of 17 control patients required treatment with
BP-lowering drugs because arterial BP elevation 160/95 mm Hg. Sys- down the rate of decline in GFR [1, 3, 5, 10, 14].
temic BP and fractional albumin clearance were both significantly lower It is well documented that elevated BP and albumin-than the control group (P  0.05).
uria are major risk factors for losing filtration power [4];
conversely, aggressive antihypertensive treatment re-
duces albuminuria and the rate of decline in GFR, which
month off-treatment effect in a limited number of pa- postpones ESRD and prolongs survival in type 1 diabetic
tients, as previously explained in detail, a significant ele- patients with nephropathy [1, 5]. Renoprotection, a ben-
vation in arterial BP, albuminuria, and GFR was clearly eficial effect on kidney function and structure above and
documented (Table 3). Albuminuria was more than dou- beyond that expected from the BP-lowering effect alone,
bled, and GFR rose 9 mL/min, which was nearly equiva- has been demonstrated using ACE inhibition in diabetic
lent to the initial GFR drop of 8 mL/min induced by and nondiabetic nephropathies [3, 5, 14]. The validity of
ACE inhibition. this concept in normotensive diabetic patients has not
Hemoglobin A1c, serum concentration of albumin, been proven since the majority of the patients enrolled
in the previously mentioned trials were hypertensive.cholesterol, sodium, potassium, and urinary sodium ex-
The Captopril Collaborative Study is an exception, sincecretion and protein intake showed no significant changes
approximately 100 normotensive type 1 diabetic patientsduring the study within or between the two groups (data
with diabetic nephropathy participated for three yearsnot shown). Five captopril-treated and six control pa-
[3]. Unfortunately, no specific information on this impor-tients developed proliferative retinopathy during the
tant subgroup has been reported. Because of its limitedeight years of study. No severe side-effects, including
power, our study does not allow for any conclusion re-hyperkalemia, occurred, and all patients continued or
garding a specific renoprotective effect of ACE inhibi-started ACE inhibition after termination of the trial.
tion. Since the worsening in GFR is a rather slow process
(low-risk patient group), the number of patients that
DISCUSSION must be enrolled in a trial aimed at elucidating a specific
Our long-term prospective randomized controlled trial renoprotective effect must be very large, probably more
in normotensive type 1 diabetic patients with diabetic than a thousand.
nephropathy indicates that ACE inhibition can arrest Even though the progression in kidney function in
the rise in systemic BP and albuminuria. Furthermore, general was slow in our patients, the condition was not
a loss in GFR is minimal in most but not all patients benign since four patients (one treated with captopril)
with diabetic nephropathy if normotension is sustained. had a sudden onset of nephrotic-range albuminuria; five
However, our study did not reveal any significant differ- patients (2 on captopril therapy) had a rate of decline in
ence in the rate of GFR decline between the two groups, GFR above 10 mL/min/year, and three control patients
which in part may reflect the relative small number of developed ESRD. Albuminuria and systolic BP acted as
subjects studied. Furthermore, the renoprotective effect progression promoters.
of ACE inhibition is underestimated because of a revers- The reduction in albuminuria could not be explained
ible hemodynamic impairment of GFR that does not by the small changes in GFR or serum albumin since a
parallel change in fractional albumin clearance occurred.attenuate over time. The initial drop in GFR induced
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Table 3. Subgroup analysis: Changes in mean arterial BP (MABP), glomerular filtration rate (GFR), and albuminuria before and after
2 months withdrawal of antihypertensive treatment (ACE inhibition vs. non-ACE inhibition) in 14 normotensive
type 1 diabetic patients with diabetic nephropathy
MABPa mm Hg GFRa mL/min/1.73 m2 Albuminuriab mg/24 h
8 years 	 8 years 	 8 years 	
8 years 2 months d 8 years 2 months d 8 years 2 months c
Captopril (N  10) 88 (8) 92 (10) 	5 (0 to 9)e 94 (40) 103 (36) 	9 (1 to 17)e 227 (2) 541 (1) 138 (52 to 271)f
Control (N  4) 97 (10) 106 (11) 	9 (5 to 13)f 89 (8) 100 (9) 	12 (6 to 17)f 935 (2) 1618 (2) 73 (16 to 255)
All (N  14) 90 (10) 96 (12) 	6 (3 to 9)f 92 (34) 102 (30) 	10 (4 to 15)f 340 (1) 739 (1) 117 (55–204)f
a Mean (SEM)
b Geometric mean (antilog SEM)
c Average relative change (%) from visit 8 years to 	2 months (95% confidence interval)
d Average absolute change from visit 8 years
e P  0.05 difference between 8 years and 8 years 	 2 months
f P  0.01 difference between 8 years and 8 years 	 2 months
Previous studies suggest that the antiproteinuric effect of it lacks sufficient statistical power to detect the small
ACE inhibition is due to diminished glomerular capillary observed differences in the rate of decline in GFR. Fi-
hydraulic pressure and/or enhanced intrinsic selectivity nally, there is an incomplete evaluation of the withdrawal
of the glomerular capillary wall [6, 15]. Recently, Imanishi of BP-lowering treatment.
et al estimated a reduction in glomerular hydraulic capil- In conclusion, the beneficial effect of ACE inhibition
lary pressure during ACE inhibition in human diabetes in arresting the rise in systemic BP and albuminuria is
[16]. A major part of the antiproteinuric effect must be long lasting. A loss of GFR is minimal in most patients
functional since it is present shortly after initiation of with diabetic nephropathy if normotension is sustained
ACE inhibition and disappears after a short pause in by prospective treatment with ACE inhibitors or is re-
treatment. stored by implementation of other antihypertensive
De Jong, Navis, and De Zeeuw have recently high- medications with the development of hypertension. The
lighted evidence suggesting that proteinuria should be renoprotective effect of ACE inhibition is underesti-
reduced as far as possible in diabetic and nondiabetic mated due to a reversible hemodynamic impairment of
nephropathies [17]. First, a reduction in proteinuria GFR that does not attenuate over time.
when patients start antihypertensive treatment predicts
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